Replies to post #644887 on ORIONS Money Stocks

[stock1ace1]

Cing .82 adhd pill phase 3 complete / partnership / licensing news watch

Heres a picture of Adhd PILL->. https://ibb.co/LhgT9XV


FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
May 21, 2024 09:00 ET

We are pleased with the FDA’s guidance and perspective regarding our pathway to a timely NDA filing, and we will proceed to complete all remaining requirements accordingly,” said Cingulate Chairman and CEO Shane J. Schaffer. “We also believe this communication provides additional go-to-market momentum as we continue to meet with potential partners for the outlicensing of CTx-1301 in the United States and abroad. Now that we have a clear path to submission, we look forward to engaging with key payer stakeholders to achieve maximum access and market penetration to benefit ADHD patients and their families.”